Nothing Special   »   [go: up one dir, main page]

DK3140303T3 - Imidazo[4,5-c]quinolin-2-onforbindelser og anvendelse deraf ved behandling af cancer - Google Patents

Imidazo[4,5-c]quinolin-2-onforbindelser og anvendelse deraf ved behandling af cancer Download PDF

Info

Publication number
DK3140303T3
DK3140303T3 DK15724351.0T DK15724351T DK3140303T3 DK 3140303 T3 DK3140303 T3 DK 3140303T3 DK 15724351 T DK15724351 T DK 15724351T DK 3140303 T3 DK3140303 T3 DK 3140303T3
Authority
DK
Denmark
Prior art keywords
methyl
quinolin
imidazo
pyridin
fluoro
Prior art date
Application number
DK15724351.0T
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3140303T3 publication Critical patent/DK3140303T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (18)

1. Forbindelse med formlen (I):
eller et farmaceutisk acceptabelt salt deraf, hvor: Q er en cyclobutyl- eller cyclopentylring, som hver eventuelt er substitueret med én hydroxy- eller methoxygruppe, eller Q er en oxetanyl-, tetrahydrofuranyl- eller oxanylring, som hver eventuelt er substitueret med én methylgruppe; R1 er methyl; R2 er hydrogen eller methyl; eller R1 og R2 sammen udgør en azetidinyl-, pyrrolidinyl- eller piperidinylring; R3 er hydrogen eller fluor; R4 er hydrogen eller methyl; og R5 er hydrogen eller fluor.
2. Forbindelse med formlen (I) ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor Q er cyclobutyl, 1-methoxycyclobut-3-yl, l-hydroxycyclobut-3-yl, 3- methoxycyclopent-l-yl, oxetan-3-yl, tetrahydrofuran-3-yl, oxan-3-yl, oxan-4-yl eller 4-methyloxan-4-yl.
3. Forbindelse med formlen (I) ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor Q er 1-methoxycyclobut-3-yl, l-hydroxycyclobut-3-yl eller oxan-4-yl.
4. Forbindelse med formlen (I) ifølge krav 1 eller krav 2 eller et farmaceutisk acceptabelt salt deraf, hvor R1 er methyl, og R2 er hydrogen eller methyl.
5. Forbindelse med formlen (I) ifølge et hvilket som helst af de foregående krav eller et farmaceutisk acceptabelt salt deraf, hvor R3 og R5 begge er hydrogen.
6. Forbindelse med formlen (I) ifølge et hvilket som helst af de foregående krav eller et farmaceutisk acceptabelt salt deraf, hvor R4 er methyl.
7. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf ifølge krav 1, hvor: Q er l-methoxycyclobut-3-yl, l-hydroxycyclobut-3-yl, 3-methoxycyclopent-l-yl, oxetan-3-yl, oxan-3-yl, oxan-4-yl eller 4-methyloxan-4-yl; R1 er methyl; R2 er hydrogen eller methyl; eller R1 og R2 sammen udgør en azetidinyl-, pyrrolidinyl- eller piperidinylring; R3 er hydrogen eller fluor; R4 er hydrogen eller methyl; og R5 er hydrogen eller fluor.
8. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående af: 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxan-4-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-1-(cis-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-3-methyl-l-(4-methyloxan-4-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxetan-3-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-1- (cis-3-hydroxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-l- (cis-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(4-methyloxan-4-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-3-methyl-l-(oxan-4-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-3-methyl-l-(oxetan-3-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-3-methyl-l- [(3R)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-7-fluor-3-methyl-l-[(3S)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-1-(cis-3-methoxycyclobutyl)-3H-imidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-1-(oxan-4-yl)-3H-imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(azetidin-l-yl)propoxy]pyridin-3-yl]-1-(cis-3-hydroxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 1-(3-cis-hydroxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-[(3R)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-[(3 S)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)-2-fluorpyridin-3-yl]-1-(cis-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)-2-fluorpyridin-3-yl]-7-fluor-1-(cis-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)-2-fluorpyridin-3-yl]-3-methyl-l-[(3S)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)-2-fluorpyridin-3-yl]-3-methyl-l-(oxan-4-yl)imidazo[5,4-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)-2-fluorpyridin-3-yl]-3-methyl-l-[(3R)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 7-fluor-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)-3-pyridyl]-1-[(3 S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 7- fluor-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)-3-pyridyl]-1-[(3 S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8- [6-(3-dimethylaminopropoxy)pyridin-3-yl]-1-[(IR,3R)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-1-[(lS,3S)-3-methoxycyclopentyl]-3-methylimidazo[4,5-c]quinolin-2-on; 7-fluor-l-(cis-3-methoxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]quinolin-2-on; 1-(cis-3-methoxycyclobutyl)-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy) pyridin-3-yl]imidazo[4,5-c]quinolin-2-on; 3-methyl-l-[(3 S)-oxan-3-yl]-8-[6-(3-pyrrolidin-l-ylpropoxy)pyridin-3-yl]imidazo[5, 4-c]quinolin-2-on; 3-methyl-l-(oxan-4-yl)-8-[6-(3-pyrrolidin-l-ylpropoxy)pyridin-3-yl]imidazo[5,4-c]quinolin-2-on; 3-methyl-l-[(3 S)-oxan-3-yl]-8-[6-(3-piperidin-l-ylpropoxy)pyridin-3-yl]imidazo[5,4-c]quinolin-2-on; 3-methyl-l-[(3R)-oxan-3-yl]-8-[6-(3-piperidin-l-ylpropoxy)pyridin-3-yl]imidazo[5,4-c]quinolin-2-on; 1-(cis-3-methoxycyclobutyl)-3-methyl-8-[6-(3-piperidin-l-ylpropoxy)pyridin-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(azetidin-l-yl)propoxy]pyridin-3-yl]-3-methyl-l-[(3R)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; 1-(cis-3-methoxycyclobutyl)-8-[6-(3-pyrrolidin-l-ylpropoxy) pyridin-3-yl]-3H-imidazo[4,5-c]quinolin-2-on; 1-(oxan-4-yl)-8-[6-(3-piperidin-l-ylpropoxy)pyridin-3-yl]-3H-imidazo[4,5-c]quinolin-2-on; 3-methyl-l-(oxan-4-yl)-8-[6-(3-piperidin-l-ylpropoxy)pyridin- 3- yl]imidazo[5,4-c]quinolin-2-on; 8-[6-[3-(azetidin-l-yl)propoxy]pyridin-3-yl]-1-(cis-3-methoxycyclobutyl)-3-methylimidazo[4,5-c]quinolin-2-on; 8-[6-[3-(azetidin-l-yl)propoxy]pyridin-3-yl]-3-methyl-l-(oxan- 4- yl)imidazo[5,4-c]quinolin-2-on; 3-methyl-8-[6-(3-methylaminopropoxy)pyridin-3-yl]-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-on; 3-methyl-8-[6-(3-methylaminopropoxy)pyridin-3-yl]-1-[(3 S)-oxan-3-yl]imidazo[5,4-c]quinolin-2-on; og 1-(cis-3-methoxycyclobutyl)-3-methyl-8-[6- (3-methylaminopropoxy)pyridin-3-yl]imidazo[4,5-c]quinolin-2-on; 3-methyl-8-[6-[3-(methylamino)propoxy]-3-pyridyl]-1-[(3R)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-methyl-l-[(3R)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-methyl-l-[(3 S)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; l-cyclobutyl-8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 7-fluor-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-ΙΕ (3 S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-7-fluor-3-methyl-1-[(3S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-3-methyl-l-[(3 S)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-3-methyl-l-[(3R)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; l-cyclobutyl-8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-3-methyl-l-(oxetan-3-yl)imidazo[4,5-c]quinolin-2-on; 7- fluor-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-2-on; 3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-[(3R)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; 3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-[(3 S)-tetrahydrofuran-3-yl]imidazo[4,5-c]quinolin-2-on; 3-methyl-l-(oxetan-3-yl)-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-on; l-cyclobutyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-on; l-cyclobutyl-3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-on; 3-methyl-8-[6-(3-pyrrolidin-l-ylpropoxy)-3-pyridyl]-1-[(3R)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8- [6-[3-(azetidin-l-yl)propoxy]-3-pyridyl]-3-methyl-l-[(3 S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[2-fluor-6-(3-pyrrolidin-l-ylpropoxy)-3-pyridyl]-3-methyl-l-[(3S)-tetrahydropyran-3-yl]imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-7-fluor-1-[(IR,3R)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-7-fluor-1-[(IS,3S)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 1-[(IR,3R)-3-methoxycyclopentyl]-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-on; 1—[(IS, 3S)-3-methoxycyclopentyl]-3-methyl-8-[6-[3- (1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-on; 1-[(IS, 3S)-3-methoxycyclopentyl]-3-methyl-8-[6-(3-pyrrolidin- 1-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-on; 1-[(IR,3R)-3-methoxycyclopentyl]-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo(4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-1-[(IR, 3R)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-2-fluor-3-pyridyl]-1-[(IS,3S)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on; 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-7-fluor-1-[(IR,3S)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on og 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-7-fluor-1-[(IS,3R)-3-methoxycyclopentyl]-3-methyl-imidazo[4,5-c]quinolin-2-on.
9. Forbindelse med formlen (I) ifølge krav 1, som er 8 — [ 6 — (3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxan-4- yl)imidazo[5,4-c]quinolin-2-on eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse med formlen (I) ifølge krav 1, som er 8 — [ 6 — (3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxan-4- yl)imidazo[5,4-c]quinolin-2-on.
11. Forbindelse med formlen (I) ifølge krav 1, som er et farmaceutisk acceptabelt salt af 8— [6— (3 — dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxan-4- yl)imidazo[5,4-c]quinolin-2-on.
12. Forbindelse med formlen (I) ifølge krav 1, som er en krystallinsk form (Form A) af 8—[6— (3 — dimethylaminopropoxy)pyridin-3-yl]-3-methyl-l-(oxan-4- yl)imidazo[5,4-c]quinolin-2-on, som har et røntgenpulverdiffraktionsmønster (opnået ved anvendelse af kobberstråling) med mindst to specifikke toppe ved 2-theta = 3,9 og 11,6° (plus eller minus 0,2° 2-theta).
13. Farmaceutisk sammensætning, som omfatter en forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1-12 og mindst ét/en farmaceutisk acceptabel (t) fortyndingsmiddel eller bærer.
14. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1-12 til anvendelse ved behandling.
15. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 14, hvor behandlingen er behandling af cancer.
16. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af cancer ifølge krav 15, hvor forbindelsen med formlen (I) eller et farmaceutisk acceptabelt salt deraf administreres i kombination med strålebehandling.
17. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af cancer ifølge krav 15, hvor forbindelsen med formlen (I) eller et farmaceutisk acceptabelt salt deraf administreres i kombination med mindst ét yderligere tumorhæmmende stof valgt fra gruppen bestående af cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposid, mitomycin, bendamustin, chlorambucil, cyclophosphamid, ifosfamid, carmustin, melphalan, bleomycin, olaparib, MEDI4736, AZD1775 og AZD6738.
18. Forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf til anvendelse ved behandling af cancer ifølge et hvilket som helst af kravene 15-17, hvor canceren er valgt fra gruppen bestående af colorektal cancer, glioblastom, mavecancer, ovariecancer, diffust storcellet B-cellelymfom, kronisk lymfatisk leukæmi, akut myeloid leukæmi, pianocellulært hoved-halskarcinom, brystcancer, triple-negativ brystcancer, hepatocellulært karcinom, småcellet lungecancer og ikke-småcellet lungecancer.
DK15724351.0T 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-onforbindelser og anvendelse deraf ved behandling af cancer DK3140303T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
DK3140303T3 true DK3140303T3 (da) 2018-06-06

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15724351.0T DK3140303T3 (da) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-onforbindelser og anvendelse deraf ved behandling af cancer

Country Status (38)

Country Link
US (4) US9428503B2 (da)
EP (1) EP3140303B1 (da)
JP (1) JP6505131B2 (da)
KR (1) KR102013021B1 (da)
CN (1) CN106255692B (da)
AP (1) AP2016009532A0 (da)
AR (1) AR100340A1 (da)
AU (1) AU2015257456B2 (da)
CA (1) CA2946459C (da)
CL (1) CL2016002735A1 (da)
CR (1) CR20160523A (da)
CY (1) CY1120248T1 (da)
DK (1) DK3140303T3 (da)
DO (1) DOP2016000281A (da)
EA (1) EA031674B1 (da)
ES (1) ES2670416T3 (da)
HR (1) HRP20180697T1 (da)
HU (1) HUE037558T2 (da)
IL (1) IL248397B (da)
LT (1) LT3140303T (da)
MA (1) MA39960A (da)
MX (1) MX2016014639A (da)
NI (1) NI201600166A (da)
NO (1) NO2714752T3 (da)
NZ (1) NZ726042A (da)
PE (1) PE20170403A1 (da)
PH (1) PH12016502168A1 (da)
PL (1) PL3140303T3 (da)
PT (1) PT3140303T (da)
RS (1) RS57223B1 (da)
SG (1) SG11201609164VA (da)
SI (1) SI3140303T1 (da)
SV (1) SV2016005312A (da)
TN (1) TN2016000458A1 (da)
TR (1) TR201807101T4 (da)
TW (1) TWI662034B (da)
UY (1) UY36112A (da)
WO (1) WO2015170081A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747952A (zh) * 2015-04-02 2020-10-09 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2018011283A (es) * 2016-03-21 2019-05-27 Astrazeneca Ab Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
EP3440079A1 (en) * 2016-04-07 2019-02-13 Astrazeneca AB N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MY183036A (en) 2016-12-20 2021-02-08 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
CA3049608A1 (en) * 2017-01-09 2018-07-12 Suixiong Cai Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
CN110312717B (zh) * 2017-02-27 2022-04-12 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CA3111994A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2h-imidazo[4,5-c]cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
EP3866785A1 (en) * 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
IL285761B1 (en) * 2019-03-05 2024-08-01 Astrazeneca Ab Fused tricyclic compounds are useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
CN114026097B (zh) * 2019-07-10 2024-02-23 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
JP2022548055A (ja) * 2019-09-12 2022-11-16 上海瑛派▲薬▼▲業▼有限公司 置換イミダゾキノキサリン化合物およびその応用
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
CN114980900A (zh) * 2020-01-13 2022-08-30 上海华禹生物科技有限公司 N2-喹啉或异喹啉取代的嘌呤衍生物在癌症治疗中的用途
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ATE400573T1 (de) 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GEP20156267B (en) 2009-06-04 2015-04-14 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
WO2010139747A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012026233A1 (ja) 2010-08-26 2012-03-01 日立建機株式会社 建設機械
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
US20130310374A1 (en) 2010-12-06 2013-11-21 Piramal Enterprises Limited` Substituted Imidazoquinoline Derivatives
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
SI3140303T1 (en) 2018-06-29
TN2016000458A1 (en) 2018-04-04
BR112016025153A8 (pt) 2021-07-20
WO2015170081A1 (en) 2015-11-12
TWI662034B (zh) 2019-06-11
KR20160147054A (ko) 2016-12-21
NZ726042A (en) 2018-08-31
US20190185468A1 (en) 2019-06-20
SV2016005312A (es) 2017-03-16
DOP2016000281A (es) 2016-12-15
NO2714752T3 (da) 2018-04-21
KR102013021B1 (ko) 2019-08-21
JP6505131B2 (ja) 2019-04-24
CA2946459C (en) 2022-07-12
US20180134699A1 (en) 2018-05-17
CL2016002735A1 (es) 2017-02-10
UY36112A (es) 2015-10-30
RS57223B1 (sr) 2018-07-31
TW201625609A (zh) 2016-07-16
HUE037558T2 (hu) 2018-09-28
US10189834B2 (en) 2019-01-29
PT3140303T (pt) 2018-05-25
BR112016025153A2 (pt) 2017-08-15
EP3140303B1 (en) 2018-03-28
CN106255692A (zh) 2016-12-21
MX2016014639A (es) 2017-03-06
ES2670416T3 (es) 2018-05-30
PH12016502168B1 (en) 2016-12-19
US20160368920A1 (en) 2016-12-22
CY1120248T1 (el) 2019-07-10
CA2946459A1 (en) 2015-11-12
NI201600166A (es) 2017-03-13
AU2015257456A1 (en) 2016-11-24
PH12016502168A1 (en) 2016-12-19
CR20160523A (es) 2017-04-27
US9822111B2 (en) 2017-11-21
PE20170403A1 (es) 2017-05-07
PL3140303T3 (pl) 2018-08-31
US9428503B2 (en) 2016-08-30
CN106255692B (zh) 2019-02-26
TR201807101T4 (tr) 2018-06-21
AU2015257456B2 (en) 2018-02-15
SG11201609164VA (en) 2016-12-29
JP2017514877A (ja) 2017-06-08
IL248397B (en) 2019-02-28
EP3140303A1 (en) 2017-03-15
MA39960A (fr) 2018-03-28
US20150336952A1 (en) 2015-11-26
EA201692095A1 (ru) 2017-08-31
LT3140303T (lt) 2018-05-25
HRP20180697T1 (hr) 2018-06-01
AR100340A1 (es) 2016-09-28
AP2016009532A0 (en) 2016-11-30
EA031674B1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
DK3140303T3 (da) Imidazo[4,5-c]quinolin-2-onforbindelser og anvendelse deraf ved behandling af cancer
US10457679B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2016348620B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR20180070703A (ko) 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료에서의 이의 용도
WO2017153578A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2018167203A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2019057757A1 (en) 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
BR112016025153B1 (pt) "compostos de imidazo[4,5-c]quinolin-2-ona, composição farmaceutica e seu uso no tratamento de câncer